Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Pulmonary Hypertension
Clinical trial register · United States · industry-sponsored

Pulmonary Hypertension Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
Florida 14 California 13 Arizona 10 Illinois 8 Colorado 7
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Pulmonary Hypertension trials in the USA

21 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
By invitation
Multimodal Physiologic State Intelligence Study
NCT07814118Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute
Truway Health, Inc.
Observational
25,000
New York
2026-09-02
Recruiting
35Pharma Inc
Phase 1/2
126
Missouri, South Carolina
2026-09
Recruiting
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
NCT07816185Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases
Pulmovant, Inc.
Phase 3
376
Florida, Kentucky, Oregon
2026-08-31
Recruiting
Pulnovo Medical, Inc.
Not applicable
750
Arizona, Connecticut, Florida, Louisiana, Massachusetts, Michigan, New York, Ohio
2026-08-21
Recruiting
Insmed Incorporated
Phase 3
344
Florida, Oregon
2026-07-20
Not yet open
Cosmos Rx, Inc
Observational
100
Virginia
2026-07
Recruiting
Insmed Incorporated
Phase 3
344
Arizona, California, Florida, Kansas, New York, North Carolina, Ohio, Oregon
2026-01-07
Recruiting
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
NCT07333183Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases
Pulmovant, Inc.
Phase 2
20
California, Florida, Illinois, Kansas, Massachusetts, Michigan, New Mexico, North Carolina
2025-12-23
Recruiting
Observational Study of Patients Undergoing Diagnostic Right Heart Catheterization
NCT07224906Pulmonary Hypertension, Congestive Heart Failure(CHF), Valve Disease, Heart
HemoCept Inc.
Observational
50
Colorado
2025-12-01
Recruiting
Tempus AI
Not applicable
900
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana
2025-07-23
Recruiting
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
United Therapeutics
Observational
900
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-01-23
Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
NCT06526195Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
Abbott Medical Devices
Not applicable
850
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-12-13
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
Pulmovant, Inc.
Phase 2
135
Arizona, California, District of Columbia, Florida, Illinois, Iowa, Kansas, Kentucky
2024-10-29
Active, closed
Tectonic Therapeutic
Phase 2
191
Arizona, California, Colorado, Florida, Georgia, Idaho, Kentucky, Maryland
2024-09-04
Active, closed
Tenax Therapeutics, Inc.
Phase 3
230
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts
2024-01-10
Recruiting
Liquidia Technologies, Inc.
Observational
80
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kentucky, Massachusetts
2023-12-28
Recruiting
Eko Devices, Inc.
Observational
2,420
Rhode Island
2023-07-12
Active, closed
Merck Sharp & Dohme LLC
Phase 2
129
California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky, Michigan
2023-03-16
Recruiting
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
NCT04555161Pulmonary Arterial Hypertension, Pulmonary Hypertension, Right Heart Dysfunction
Aria CV, Inc
Not applicable
30
California, Indiana, Massachusetts, Minnesota, New York, Ohio, South Carolina, Wisconsin
2021-03-15
By invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
United Therapeutics
Phase 3
1,000
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa
2019-09-23
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/pulmonary-hypertension

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 11 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies listing the condition Pulmonary Hypertension.

How many Pulmonary Hypertension trials are recruiting in the US?

13 of the 21 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 5 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Pulmonary Hypertension), 21 studies
PhaseStudiesRecruitingShare
Observational6428.6%
Phase 25123.8%
Phase 35323.8%
Not applicable4419%
Phase 1/2114.8%

Most active sponsors

Lead sponsors with the most studies (Pulmonary Hypertension)
Lead sponsorStudiesRecruiting
Pulmovant, Inc.32
Insmed Incorporated22
United Therapeutics21
35Pharma Inc11
Abbott Medical Devices11
Aria CV, Inc11
Cosmos Rx, Inc10
Eko Devices, Inc.11
HemoCept Inc.11
Liquidia Technologies, Inc.11

Top states

Top states (Pulmonary Hypertension), by number of studies with a site there
StateStudies
Florida14
California13
Arizona10
Illinois8
Colorado7
Indiana6
Kentucky6
Georgia5
Massachusetts5
New York5
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.